



SPATIAL REPELLENTS

FOR CONTROL OF VECTOR-BORNE DISEASE

AN UPDATE

Neil F. Lobo / Nicole L. Achee / John Greico
University of Notre Dame
Department of Biological Sciences
Eck Institute for Global Health



What are Spatial Repellents?

Product Description and Paradigm Claim


- Spatial repellents are products designed to release volatile chemicals into the air and prevent human-vector contact within the treated space.

Deployment of spatial repellent products in enclosed and semi-enclosed spaces will reduce pathogen transmission.

PROTOTYPES



How Spatial Repellents are Expected to Function Mechanism of Action



Continual Release

Chemical Exploitation

Role of Spatial Repellents in Vector Control Filling Gaps


- **Addresses vector behavior variability**
 - day-time, early evening and/or outdoor biting
- **Facilitate coverage and reduce delivery challenges**
 - adding a consumer product distribution model (uptake enhancement)
 - top-down delivery during epidemics (dengue) and/or routinely (malaria)
 - less bulky than LLINs, IRS and/or space-spraying
- **Tools for insecticide resistance mitigation**
 - additional target sites, mode of action & functional doses beyond toxicity
- ***New paradigm to drive R&D for novel chemical actives /products***



Evidence –
Entomology and Epidemiology

Evidence of Spatial Repellents to Prevent Disease

Hill et al. *Malaria Journal* 2014, **13**:208
<http://www.malariajournal.com/content/13/1/208>

 MALARIA JOURNAL

RESEARCH Open Access

A household randomized, controlled trial of the efficacy of 0.03% transfluthrin coils alone and in combination with long-lasting insecticidal nets on the incidence of *Plasmodium falciparum* and *Plasmodium vivax* malaria in Western Yunnan Province, China

Nigel Hill^{1*}, Hong Ning Zhou^{1,2}, Flyu Wang², Xiaofang Guo², Ilona Carneiro¹ and Sarah J Moore^{3,4,5*}

Am. J. Trop. Med. Hyg., 91(6), 2014, pp. 1079–1087
doi:10.4269/ajtmh.13-0725
Copyright © 2014 by The American Society of Tropical Medicine and Hygiene

Impact of a Spatial Repellent on Malaria Incidence in Two Villages in Sumba, Indonesia

Din Syafruddin,* Michael J. Bangs, Dian Sidik, Iqbal Elyazar, Puji BS Asih, Krisin Chan, Siti Nurleila, Christian Nixon, Joko Hendarto, Isra Wahid, Hasamuddin Ishak, Claus Bøgh, John P. Grieco, Nicole L. Achee, and J. Kevin Baird

Eijkman Institute for Molecular Biology, Jakarta, Indonesia; Department of Parasitology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia; Public Health and Malaria Control, International SOS, Kuala Kencana, Papua Indonesia; Department of Entomology, Faculty of Agriculture, Kasetsart University, Bangkok 10900, Thailand; Department of Epidemiology, Faculty of Public Health, Hasanuddin University, Makassar, Indonesia; Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia; The Sumba Foundation, Bali, Indonesia; Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland; Department of Biological Sciences, Eck Institute for Global Health, University of Notre Dame, Notre Dame, Indiana; Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

Coils alone : 77% PE
LLINs alone: 91% PE
Coils + LLIN: 94% PE

Coils alone : 52% PE

32% lower outdoor landing in houses with SR



Guidance on Operational Implementation Primary VCAG Questions

- What is the product **coverage required** for protection?
- **How does efficacy vary** with geography or vector bionomics?
- Do repellents have either a **diversion or a community-wide protection effect**?
- Are current pyrethroid-based repellents **effective against resistant vector populations**?



Newly Funded Research Program (2014-2019)

Generating an Evidence Base



BILL & MELINDA
GATES foundation

- **GOAL:**
- Evaluate the public health impact of one spatial repellent product to reduce and prevent transmission of *Plasmodium* spp. and dengue viruses.
- **OBJECTIVES:**
 - Provide a quantitative estimate of **protective efficacy (PE)**
 - Provide inputs into program-relevant questions of **optimization/application**
 - Confirm and measure the **entomological correlates** of reduced infection
 - Drive efforts to acquire **full recommendation** of spatial repellent products

Scale-back of Study from Africa sites (Indonesia and Peru only)



Present status of Primary VCAG Questions

- What is the product **coverage required** for protection?
 - Indonesia (malaria) and Peru (Dengue) only
- **How does efficacy vary** with geography or vector bionomics?
 - Indonesia (malaria) and Peru (Dengue) only. **Not possible in Africa**
- Do repellents have either a **diversion or a community-wide protection effect**?
 - **Not possible** (was planned as part of the Kenya study)
- Are current pyrethroid-based repellents **effective against resistant vector populations**?
 - **Not possible** at present (possible if insecticide resistance appears)

Program updates

- **Malaria (Indonesia)**
 - Follow-up of
 - ~1240 subjects
 - from ~2,719 enrolled households
 - began April 18, 2016 (to Jan 29, 2018).
 - 28,816 Bloodspots collected
 - 47x active + passive collections
 - since December, 2016 (Intervention placed)
 - 46x HLC collections
 - 4 sentinel sites in 12 clusters have occurred following intervention.
 - SHEILDS replaced at 2 week intervals since deployment.
 - Ends in March, 2018

 - Also,
 - Puskesmas (HIS) versus active data collection
 - Effect of SR on non-vector species

Program updates

- **Peru (Dengue)**

- Weekly febrile surveillance in **16,204** persons for active virus infection has occurred as of Oct 2016
- Baseline samples from **2,017** subjects for longitudinal sero-conversion have been collected as of Oct 2016.
- Annual longitudinal follow up samples initiated in November 2017, **~800** samples obtained so far.
- SHEILDS replaced at 2 week intervals since deployment.
- Adult mosquito monitoring carried out at 2 week intervals since deployment.
- Application of 980 self-administered cell phone questionnaires determine participant perceptions and acceptability



Acknowledgements

Grantee	Kenya		Peru		Zambia			Tanzania		Indonesia	External Advisors
U. Notre Dame	CDC	KEMRI	UCDavis	NAMRU-6	Johns Hopkins University	NMCC	Macha Research Trust	Swiss TPH	Ifakara Health Institute	Eijkman Institute	
Nicole Achee (coPI)	John Gimnig (PI)	Eric Ochomo (PI)	Thomas Scott (PI)	LTC Robert Hontz (Dept. Dir. Virology)	Jennifer Stevenson (PI)	Chadwick Sikaala (PI)	Jennifer Stevenson (PI)	Sarah Moore (PI)	Bernadette Huho (Project Leader)	Din Syafruddin (PI)	Timothy Endy (Upstate Medical Univeristy)
Neil Lobo (coPI)	Mary Hamel (PI)		Amy Morrison (Proj Coord)			Busiku Hamainza (PI)			Saumu Ahmed (Study Clinician)	Puji Budi Setia Asih (Proj Coord)	Kevin J. Baird (Eijkman Oxford Research Unit)
Caleb Reinking (Data Manager)	Monica Shah (Epidem)		<p>Funding provided by:</p> <p>Bill & Melinda Gates Foundation Grant OPP1081737: "Spatial Repellent Products for Control of Vector-borne Diseases" Sr. Program Officer: Mike Reddy</p> <p>Products (and some funds) donated by:</p> <p>SC Johnson Collaborator: Maude C. Meier, Curtis Conklin, David Eland, Tom Putzer</p>						Daniel Msellemu (Data Manager0)	Agustinus M. Silaban / Joko Hendarto (Parasitol)	Audrey Lenhart (CDC)
Jared Olsen (Data Programmer)									Jason Moore (Logistician)	Dendi Hadi Permana / Lepa S (Entomol)	Frank Collins (U. Notre Dame)
David Pettifor (Data Programmer)									Hassan Ngonyani (Ent. Tech)	Dian Sidik Arsyad (Epidem)	Kate Aultman (Stelma Consulting)
Fang Liu (Statistician)									Edgar Mbeleya (Ent. Tech)	Ismail Ekoprayitno (Data Mngr)	FHI 360
Marianne Raybaud (Coordinator)									Emmanuel Simfukwe (Ent. Tecn)	Michael Bangs (Advisor)	Zen Hafy (Manager)
John P. Grieco (Advisor)									Antone Mseka (Ent. Tech)	Claus Bogh (Advisor)	Ahmed Goolam (Monitor)



SPATIAL REPELLENTS

FOR CONTROL OF VECTOR-BORNE DISEASE

Thank you


nachee@nd.edu (Nicole Achee)

nlobo@nd.edu (Neil Lobo)

jgrieco@nd.edu (John Grieco)



Progress on Public Health Value



Next steps (TBD):
Pilot implementation trial
Expansion of malaria trial
Expansion of dengue trial